Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Grant Shapps vows he WILL find more planes for mass parachute drop to mark 80th anniversary of D
The perfect introduction to Wainwright's Lake District world
HKFP Lens: Hong Kong press group announces winners of annual news photo contest
China's Xi Jinping delivers unexpected speech at UN hours after US President Joe Biden speaks
Padres second baseman Xander Bogaerts leaves game against Braves with shoulder injury
the remote Canadian Island known as MARS on earth! It is so otherworldly, NASA uses it for research
3 jailed for Hong Kong's priciest art heist, after selling billion
The perfect introduction to Wainwright's Lake District world
It's no wonder parents are taking their children on holiday during term time! Sky
Go on holiday for just £6.40 with the Mail experts' guide to the best bargain trips
Why US Catholics are planning pilgrimages in communities across the nation
HK$3.5 billion Hong Kong Palace Museum opens after typhoon delay